InvestorsHub Logo
icon url

boi568

07/16/22 5:00 AM

#366342 RE: Investor2014 #366341

Given the relatively low n of 509 for a pivotal trial in a major indication, it appears that Missling is relying on a large clinical benefit to carry the day with the FDA.